We assessed an in-vitro model of hyperfibrinolysis using rotational thromboelastometry (ROTEM) by the addition of increasing concentrations of tissue-type plasminogen activator (t-PA) on whole blood obtained from children undergoing cardiac surgery. We assessed the relevance of this model by repeating the tests in the same population after tranexamic acid (TXA) infusion. In addition, we determined the sensitivity and specificity of ROTEM parameters to detect the different degrees of fibrinolysis. Blood samples obtained from 20 children were analyzed at two predefined timepoints: after induction of anesthesia, before TXA (baseline), and at the end of surgery during TXA infusion (end surgery). At baseline, an extrinsic activation with tissue factor (EXTEM) test was performed without and with increasing concentration of t-PA (102, 255, 512, 1024, 1535, and 2539 units t-PA/ml). At the end of surgery, a second EXTEM test was performed without and with two different t-PA concentrations (1535 and 2539 units t-PA/ml). At baseline, increasing t-PA concentrations in the EXTEM test induced a gradual increase of hyperfibrinolysis characterized by a reduction in clot firmness and stability parameters. In the presence of TXA, t-PA-induced hyperfibrinolysis was completely abolished. Lysis-onset time (LOT) and degree of fibrinolysis measured at 30 min (LI30) best assessed the degree of fibrinolysis. This in-vitro model of t-PA-induced hyperfibrinolysis using the EXTEM test of ROTEM may represent a promising tool to assess hyperfibrinolysis in the pediatric population. In addition, we observed that LOT and LI30 should be considered as the best parameters to detect different degrees of fibrinolysis.
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Introduction
Bleeding after cardiopulmonary bypass (CPB) is a major cause of hemodynamic instability and transfusion requirement, which lead to increase morbidity, mortality, and costs [1] . Cause of the coagulopathy induced during and after pediatric cardiac surgery is multifactorial and relatively specific [2] . Among the different factors implicated, the activation of fibrinolysis has been shown to play a major role, which prompted the use of antifibrinolytic agents like tranexamic acid (TXA) [3, 4] .
Although TXA administration significantly decreases blood loss and transfusion requirement in these conditions [5] , several concerns remain regarding the paucity of pharmacokinetic studies, as well as the lack of knowledge about the 'optimal' concentration to be targeted in the plasma [6] .
The determination of such concentration will require adequate and reproducible tests to assess the degree of fibrinolysis in vivo, as well as accurate pharmacokinetic data to define the TXA infusion scheme associated with the lowest TXA plasmatic concentration that will adequately inhibit this in-vivo fibrinolysis activation [7] .
Unfortunately, the evaluation of fibrinolysis using standard laboratory tests remains difficult. Also, standard viscoelastic tests are not sensitive enough to detect the small increases in fibrinolytic activity [8] . Two studies have previously reported that increasing concentration of tissue-type plasminogen activator (t-PA) is associated with a concentration-dependent increase in hyperfibrinolysis assessed with thromboelastography [9, 10] . The first objective of the present study was to develop an invitro model of hyperfibrinolysis using rotational thromboelastometry (ROTEM) by the addition of increasing concentrations of t-PA to whole blood obtained from children undergoing cardiac surgery. At the end of the surgery, although children received continuous TXA infusion, the same experimental approach was repeated with the aim of evaluating the reliability of our model. The second objective of the study was to determine the sensitivity and the specificity of ROTEM parameters to detect different degrees of hyperfibrinolysis.
Methods
After Anesthetic management was standardized during the whole study period. A standard monitoring procedure, including pulse oxymetry, noninvasive blood pressure, 5-leads electrocardiogram, arterial and central venous pressures, urinary output, and rectal and cutaneous temperature probes, was used in all children. General anesthesia consisted of midazolam, sufentanil, and rocuronium in all children, with the exception of those with univentricular physiology undergoing a cavopulmonary connection. In this particular situation, sevoflurane, remifentanil, and atracurium were used to ensure that children would be extubated at the end of the surgery. TXA was systematically administered (10 mg/kg loading dose before CPB, 10 mg/kg per h until chest closure, and 10 mg/kg in the CPB prime). All children received 30 mg/kg methylprednisolone and cefazoline 25 mg/kg after induction of anesthesia. Unfractionated heparin (UFH, 4 mg/kg loading dose) was administered before aortic cannulation to achieve activated clotting time (ACT; ACTII monitor, Medtronic BV, Kerkrade, the Netherlands) above 480 s. The CPB priming was standardized according to our local practices and contained a combination of a colloid, 20% mannitol (1.5 ml/kg), 20 mEq/l sodium bicarbonate, 50 mg/ l UFH, and cefazoline 25 mg/kg. At the end of CPB, protamine was administered (half of the total UFH dose administrated during the whole CPB duration) to neutralize heparin activity.
Blood samples
Samples were obtained from the arterial line allowing for three times the dead space before 2.7 ml of blood were added in a citrated tube (BD Vacutainer Plus Plastic Citrate Tube, BD Plymouth, UK). Two blood samples were drawn: the first at baseline after anesthesia induction right before the administration of the TXA loading dose, and the second, after CPB, 10 min after the protamine administration and the control of adequate heparin neutralization during TXA infusion.
In-vitro protocol Analyses were performed within 30 min after blood samples were obtained. The following parameters were determined using the EXTEM test of the ROTEM monitor: the clot amplitude measured after 5, 10, 20, and 30 min (A5, A10, A20, and A30: mm); the maximum clot firmness (MCF: mm); the clot lysis index at 30 min (LI30: %) corresponding to the percentage of remaining clot stability in relation to the MCF value 30 min after the clotting time; and the maximum lysis (%). The lysisonset time (LOT: s), defined as the time to initiation of fibrinolysis; the maximum lysis (ML: s), defined as the time between clotting time (CT: s) and the start of significant lysis (15% decrease of the amplitude compared with MCF), and the clot lysis rate (CLR: degree), defined as the strongest lysis described by the angle between the baseline and the tangent to the declining firmness curve, were also analyzed.
In the first blood sample, seven analytical conditions per patient were analyzed with the EXTEM test of the ROTEM: the first one without addition of t-PA and the other six with the addition of increasing doses of t-PA (alteplase, Actilyse; Boehringer Ingelheim Internation GmbH, Ingelheim am Rhein, Germany) to achieve the following concentrations: 102, 255, 512, 1024, 1535, and 2539 units t-PA/ml. Concentrations were determined based on the previous research showing that a t-PA concentration of 100 ng/ml causes a maximum lysis of approximately 15% [9] , whereas t-PA concentrations greater than 1500 ng/ml are needed to obtain a supramaximal activation of hyperfibrinolysis [11] . We obtained different t-PA concentrations using different dilution of alteplase, allowing the addition of a constant (6-9 ml) and minimal t-PA volume to whole-blood sample (297-294 ml).
In the second blood sample, after CPB, once UFH has been neutralized with protamine, and the adequate neutralization confirmed, three sets of analyses were performed one without t-PA and two others with the two maximal doses of t-PA (i.e. 1535 and 2539 units t-PA/ ml, respectively).
Statistical analysis
The Kolmogorov-Smirnov test was used to assess the normality of our population. . The probability of 50% (ED50) and 95% (ED95) efficacy, as well as their associated 95% confidence intervals (95% CIs) were obtained. These parameters were used to calculate the t-PA concentration required to achieve a 50% and a 95% decrease in the measured ROTEM parameters.
Receiver operating characteristics (ROC) curves were constructed with the different ROTEM variables with the aim to determine the parameters that best assessed different degrees of hyperfibrinolysis: A5, A10, A20, A30, MCF, LI30, maximum lysis, LOT, and CLR. Area under the ROC curve (AUC) with the 95% CI, Younden criterion, sensitivity, and specificity were calculated.
Results
We obtained whole blood from 20 children undergoing cardiac surgery (10 with cyanotic disease and 10 with noncyanotic disease). Demographic characteristics of the studied population are presented in Table 1 . No children received hemostatic products (fresh frozen plasma, platelet concentrates, cryoprecipitate, or fibrinogen concentrate) before the second blood sample was obtained.
Plasma tissue-type plasminogen activator and fibrinolysis parameters At baseline, the addition of increasing t-PA concentrations to blood samples induced a gradual increase in hyperfibrinolysis ( Fig. 1 ), characterized by a dramatic reduction of both clot firmness (Fig. 2a ) and lysis parameters (Figs 3a and 4a ). In the presence of TXA, the effect of maximal t-PA-induced hyperfibrinolysis was completely abolished even at the highest t-PA concentrations (Figs 2b, 3b, and 4b) . Plasma tissue-type plasminogen activator and maximal fibrinolysis measured on clot lysis index at 30 min The t-PA concentration-effect allowed the determination of the ED50 and the ED95 for the LI30 parameter: 295.4 units t-PA/ml (263.0-329.9) and 530.4 units t-PA/ ml (325.7-735.1; Fig. 5 ). After CPB, no concentrationeffect analysis could be performed as the in-vitro t-PAinduced hyperfibrinolysis was completely inhibited.
Sensitivity and specificity of rotational thromboelastometry to detect hyperfibrinolysis Table 2 reports the results of the ROC analyses obtained for the ROTEM parameters at different degrees of fibrinolysis. Using these analyses, we observed that LI30 and LOT best assessed the degree of hyperfibrinolysis. Indeed, at minimal fibrinolysis activation (102 units t-PA/ml), AUC for LI30 was 0.74 (95% CI: 0.58-0.87) and 0.77 (95% CI: 0.47-0.95) for LOT. We observed that LI30 equal or less than 97% was associated with a specificity of 90% and a sensitivity of 50% to detect the lowest degree of hyperfibrinolysis (t-PA: 102 units t-PA/ml), whereas LI30 equal or less than 81% offered both specificity and sensitivity of 100% to detect high degree of hyperfibrinolysis (t-PA: 512 units t-PA/ml). In addition, we observed that LOT equal or less than 2276 s offered a specificity of 87% and a sensitivity of 80% to detect the lowest degree of hyperfibrinolysis (t-PA: 102 units t-PA/ ml), whereas LOT equal or less than 1719 s is associated with a specificity and a sensitivity of 100% to detect high degree of hyperfibrinolysis (t-PA: 512 units t-PA/ml). Although other parameters allowed the detection of extreme hyperfibrinolysis, these factors were not adequate to detect the lowest level of hyperfibrinolysis.
Discussion
Our study is the first to detail an experimental model of t-PA-induced hyperfibrinolysis using the EXTEM test of ROTEM on whole blood obtained from children undergoing cardiac surgery with CPB. Interestingly, the TXA infusion scheme administered in our population completely inhibited the in-vitro-induced hyperfibrinolysis, Lysis parameters obtained at different t-PA concentrations at baseline (a) and after cardiopulmonary bypass (b). CLR, clot lysis ratio (degree); LI30, lysis measured at 30 min (%); ML, maximum lysis (%); t-PA, tissue-type plasminogen activator.
even in the presence of very high concentrations of t-PA. Among the different ROTEM parameters evaluated, we determined that LOT and LI30 offered the best sensitivity and the best specificity to detect different degrees of hyperfibrinolysis.
TXA is frequently used in children undergoing cardiac surgery to decrease perioperative bleeding and transfusion requirements [12, 13] . However, the lowest infusion scheme capable of completely blocking the fibrinolysis observed during and after cardiac surgery remains to be defined. It is only recently that the pharmacokinetic profile of TXA in children undergoing cardiac surgery has been determined [14] . Grassin-Delyle et al. [14] reported that a bolus dose of 6.4 mg/kg followed by a continuous infusion ranging between 2 and 3.1 mg/kg per h could enable the maintenance of plasma TXA concentrations between 20
and 30 mg/ml that should be effective in inhibiting in-vivo fibrinolysis. However, old pharmacodynamic studies performed in adult cardiac surgery patients indicated that concentrations between 100 and 126 mg/ml are required to completely block fibrinolysis [15, 16] . The unequivocal effective target TXA concentration in adult and children cardiac population remains still to be determined.
The evaluation of fibrinolysis either using standard laboratory tests or viscoelastic tests remains difficult. Although viscoelastic tests have already been used to assess fibrinolysis, their sensitivity in this context remains poorly evaluated [17, 18] . In a prospective cohort study, Raza et al. [8] assessed the prevalence and the severity of fibrinolysis in trauma patients measured by the increase in plasmin generation, determined by the measurement of plasmin-antiplasmin (PAP) complex levels. A secondary objective of this study was to assess whether this fibrinolysis could be detected using ROTEM. The authors reported that increased fibrinolysis was not detected by ROTEM. Therefore, based on the available literature, either ROTEM or thromboelastogram (TEG) does not appear to have the sensitivity to detect small increases in fibrinolytic activity [19] .
In a recent in-vitro study, Yee et al. [11] assessed the minimal concentration of TXA needed to completely inhibit fibrinolysis. In neonatal plasma samples derived from the cord blood, the authors evaluated hyperfibrinolysis activated with 1000 units t-PA/ml through the measurement of the LY30, a parameter assessing fibrinolysis on the TEG. They observed that neonatal plasma required significantly lower TXA concentration to completely inhibit fibrinolysis than adult plasma (6.54 mg/ml, 95% CI: 5.19-7.91 vs. 17.5 mg/ml, 95 CI: 14.59-20.4). However, these results should be interpreted taking into account several limitations. First, this study was performed using cord blood and not whole blood, and therefore some information like MCF, which is also linked to platelet concentrations, could be missing. Second, the authors arbitrarily used 1000 units t-PA/ml as the 'ideal' concentration of this agent to maximally activate hyperfibrinolysis after pooling 20 samples of cord blood. The use of individual plasma samples would have allowed the calculation of the ED50 and ED95 of t-PA.
In our study, we used individual whole blood drawn from children undergoing cardiac surgery. We observed that the addition of increasing concentration of t-PA to blood samples at baseline led to a progressive activation of hyperfibrinolysis, which followed a sigmoidal relationship. Our objective was to determine the t-PA concentration that would create extreme activation of hyperfibrinolysis, corresponding to the lowest LI30 and the lowest clot firmness. Although this in-vitro model has already been used in different studies [9, 10, 20] , our study is the first to describe the relationship between t-PA concentration and the degree of hyperfibrinolysis induced in whole blood obtained from children with congenital heart disease. We also observed that the administration of a 10 mg/kg TXA loading dose followed by a continuous infusion of 10 mg/kg per h and a 10 mg/kg bolus in the CPB prime completely inhibits the in-vitro t-PA-induced hyperfibrinolysis even at the highest t-PA concentration used. This observation supported our hypothesis that this experimental model could be relevant to assess the antifibrinolytic effect of TXA administration on an individual basis. Our TXA infusion scheme appears to be extremely effective to inhibit hyperfibrinolysis in our in-vitro model even in the presence of very high concentrations of t-PA. Even more, our results also suggest that our current dosing scheme might be unnecessarily high, potentially exposing our children to a risk of overdosage. These observations also support the need for the determination of an optimal dosing scheme that could be effective and safe for the pediatric cardiac population. This in-vitro model will now be used in a further study, in which increasing TXA concentrations are used to inhibit hyperfibrinolysis induced by a single t-PA concentration. The aim of this second study will be to determine the 'ideal' TXA concentration needed to obtain a complete inhibition of hyperfibrinolysis.
According to the manufacturer, different ROTEM parameters could be used to detect increased fibrinolysis [maximum lysis and lysis index measured at different time (e.g. LI30)]. In a recent retrospective study, Dirkmann et al. [21] reported that decreased values of clot firmness measured early (e.g. decreased A5) on EXTEM are associated with fibrinolysis and improved its early detection. Although early detection of fibrinolysis could be interesting, a decrease in clot amplitude could not be considered as a specific marker of increased fibrinolysis as this could be explained by hemodilution, decreased clot factors concentration, and thrombocytopenia [22] . In another recent study, Dekker et al. [20] observed that LOT might be used for the fast detection of severe hyperfibrinolysis with a better resolution than maximum lysis. Our study confirmed that LOT and, as a second choice, LI30 could be considered as the best parameters to detect different degrees of hyperfibrinolysis. Although these results are interesting, these observations need to be confirmed in further in-vivo studies.
Our study presents some limitations. On one hand, fibrinolysis is a physiological pathway to dissolve the clot in the circulation. During cardiac surgery, the surgical trauma, contact of blood with the nonendothelial surfaces, ischemia-reperfusion (I/R) phase, and hypothermia will activate several cascades including cellular and plasmatic components that could lead to excessive fibrinolysis [23] . Thus, fibrinolysis involves several complex regulatory mechanisms that could not be solely assessed by ROTEM. However, in this experimental study, our goal was to design a 'simple' reproducible experimental model of hyperfibrinolysis that could be easily used in different clinical conditions. Although this model required additional volume of t-PA, we used different dilution for the t-PA solution in order to decrease and standardize the volume added in the blood sample. On the other hand, such design could not be easily compared to the clinical conditions observed during CPB. The plasmatic t-PA concentration measured in children during CPB has been found to be around 4 units t-PA/ml, which is far below the concentration used in our experimental study [24] . However, this plasmatic concentration may not reflect the amount of t-PA that could be released locally by the damaged tissue.
In summary, our study is the first to describe an experimental model of t-PA-induced hyperfibrinolysis using the EXTEM test of ROTEM on whole blood obtained from small children undergoing cardiac surgery with CPB. We observed that LOT and LI30 should be considered as the best parameters to detect the different degrees of hyperfibrinolysis. The present results suggest that this model may be a surrogate method to mimic in-vivo fibrinolysis, being a potential useful tool to determine the optimal plasmatic TXA concentration required to inhibit hyperfibrinolysis.
